| Literature DB >> 31615509 |
Amena El-Harakeh1,2, Rami Z Morsi3, Racha Fadlallah1,4, Lama Bou-Karroum1,4, Tamara Lotfi3,5, Elie A Akl6,7,8,9.
Abstract
BACKGROUND: Given the considerable efforts and resources required to develop practice guidelines, developers need to prioritize what topics and questions to address. This study aims to identify and describe prioritization approaches in the development of clinical, public health, or health systems guidelines.Entities:
Keywords: Guideline development; Guidelines; Health priorities; Methodology; Prioritization approaches; Priority setting; Research prioritization
Mesh:
Year: 2019 PMID: 31615509 PMCID: PMC6792189 DOI: 10.1186/s12913-019-4567-2
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Preferred reporting items for systematic reviews and meta-analyses (PRISMA) study flow diagram for selection
General characteristics of the approaches for prioritizing guideline topics
| Paper | Lead entity | Target audience | Field (specific domain) | Focus of prioritization | Type of guideline development |
|---|---|---|---|---|---|
| Battista, 1995 [ | Independent researchers | Canadian guideline developing groups | Clinical | Topics | De novo |
| Field, 1995 [ | Institute of Medicine | Agency for Health Care Policy and Research | Clinical | Topics | De novo |
| McClarey, 1999 [ | Royal College of Nursing (RCN) | RCN guideline developers | Clinical, nursing | Topics (e.g., hyperplasia, colon cancer, breast cancer, wound care, etc.) | De novo |
| Oxman, 2006 [ | WHO Advisory Committee on Health Research | WHO entities developing guidelines | Health care | Topics or interventions | De novo |
| Ketola, 2007 [ | ‘Current Care’ | Guideline developers | Clinical | Topics (e.g., benign prostatic hypertrophy, brain injuries in adults, atrial fibrillation, cataract, etc.) | De novo |
| Reveiz, 2010 [ | Independent researchers | Guideline developers within developing countries | Clinical | Topics | De novo |
| Atkins, 2012 [ | Independent researchers | Guideline developers in respiratory diseases | Clinical, respiratory diseases | Topics | De novo |
| Schünemann, 2014 [ | Independent researchers | Guideline developers | Clinical, Public health and Health systems | Topics | De novo |
| Reddy, 2014 [ | Independent researchers | National Institute for Health and Care Excellence (NICE) | Public health | Topic (e.g., sickle cell screening, substance misuse, water fluoridation, etc.) | De novo |
| Mounesan, 2016 [ | Tehran University of Medical Sciences | Guideline developers | Clinical, family medicine | Topics (e.g., anemia, osteoporosis, indigestion/dyspepsia, pneumonia, etc.) | De novo |
Steps of the development process of the approaches for prioritizing guideline topics
| Paper | Peer-reviewed literature | Grey literature | Consensus building | Ranking of proposed prioritization criteria | Pilot testing | Conducting primary research | Stakeholder involvement |
|---|---|---|---|---|---|---|---|
| % papers reporting the step | 70% | 90% | 60% | 50% | 40% | 40% | 90% |
| Battista, 1995 [ | ✓ | ✓ | ✓ | ✓Mailed survey | ✓ | ||
| Field, 1995, 1995 [ | ✓ | ✓ | ✓ | ✓ | |||
| McClarey, 1999 [ | ✓ | ✓ | |||||
| Oxman, 2006 [ | ✓ | ✓ | ✓ | ||||
| Ketola, 2007 [ | ✓ | ✓ | ✓ | ✓ | ✓Phone interviews | ✓ | |
| Reveiz, 2010 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓Online survey | ✓ |
| Atkins, 2012 [ | ✓ | ✓ | |||||
| Schünemann, 2014 [ | ✓ | ✓ | ✓ | ✓ | |||
| Reddy, 2014 [ | ✓ | ✓ | ✓ | ✓ | |||
| Mounesan, 2016 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ Interviews | ✓ |
Aspects proposed to be addressed when prioritizing guideline topics
| Paper | When to conduct prioritization? | How to generate an initial list of topics? | What criteria to use? | What stakeholders to involve? | Documentation |
|---|---|---|---|---|---|
| % papers reporting the aspect | 10% | 60% | 100% | 90% | 40% |
| Battista, 1995 [ | ✓ | ✓ | ✓ | ||
| Field, 1995 [ | ✓ | ✓ | |||
| McClarey, 1999 [ | ✓ | ✓ | ✓ | ||
| Oxman, 2006 [ | ✓ | ✓ | ✓ | ||
| Ketola, 2007 [ | ✓ | ✓ | ✓ | ||
| Reveiz, 2010 [ | ✓ | ✓ | ✓ | ||
| Atkins, 2012 [ | ✓ | ✓ | ✓ | ✓ | |
| Schünemann, 2014 [ | ✓ | ✓ | ✓ | ✓ | |
| Reddy, 2014 [ | ✓ | ||||
| Mounesan, 2016 [ | ✓ | ✓ | ✓ | ✓ |
Steps proposed for generating an initial list of topics when prioritizing guideline topics
| Study | Description |
|---|---|
| Battista, 1995 [ | Not reported |
| Field, 1995 [ | Not reported |
| McClarey, 1999 [ | 1. Collect data using questionnaire from RCN professional groups and other RCN databases. 2. Collect information on patient priorities from representative groups and the literature. 3. Group topics by themes and accept that some might be arbitrary. |
| Oxman, 2006 [ | Not reported |
| Ketola, 2007 [ | 1. Need for a new guideline arises in a specialist society or other source. 2. PRIO-tool from the ‘Current Care’ web site ( |
| Reveiz, 2010 [ | A thematic team (experts in the field and methodological consultant) would suggest three to five clinical topics that could potentially be selected for developing a clinical practice guideline. |
| Atkins, 2012 [ | 1. Survey clinicians, experts, and patients for candidate topics. 2. Create a list of topics using formal or informal (e.g., review of other guidelines). 3. Allow stakeholders to comment on scope and specific questions. 4. Identify issues arising from new and emerging technologies and treatments. |
| Schünemann, 2014 [ | 1. Decide who will oversee the process (e.g., priorities of the government, funding agency or professional society). 2. Apply specific criteria and use a transparent and systematic process to guide the suggestions of guideline topics. |
| Reddy, 2014 [ | Not reported |
| Mounesan, 2016 [ | 1. Topic identification should be informed by evidence including: scientific evidence, available reports, expert opinion and/or needs assessment 2. Topic identification should be done separately for: prevention, diagnosis and treatment |
Common framework of the guideline topics prioritization criteria and their respective domains
| Items | Disease-related factors | Interest | Practice | Guideline development | Potential impact of the intervention | Implementation considerations | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health burden | Economic burden | Burden on healthcare system | Equity relevance | Urgency | Health professional level | Consumer level | National level | Practice variation | Uncertainty or controversy about best practice | Absence of guidance | Unsatisfactory guidance | Availability of evidence | Potential for changing existing guidance | Impact on health outcomes | Economic impact | Impact on the healthcare system | Impact on equity/access | Feasibility of intervention implementation | Availability of resources | |
| Paper | ||||||||||||||||||||
| % papers reporting the criterion | 100 | 50 | 30 | 50 | 10 | 40 | 40 | 20 | 80 | 40 | 50 | 50 | 50 | 50 | 70 | 50 | 40 | 20 | 40 | 30 |
| Battista, 1995 [ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||
| Field, 1995 [ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||
| McClarey, 1999 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Oxman, 2006 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||
| Ketola, 2007 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
| Reveiz, 2010 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| Atkins, 2012 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
| Schünemann, 2014 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||
| Reddy, 2014 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||
| Mounesan, 2016 [ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||
Proposed types of stakeholders to involve in prioritizing guideline topics and the method for their involvement
| Paper | Number | Involvement method | Type |
|---|---|---|---|
| Battista, 1995 [ | Not reported | Not reported | • Members of guideline developing organizations • Potential end users • Patient representatives • Public |
| Field, 1995 [ | Not reported | Delphi or Delphi-like techniques | • Experts • Potential end users (clinicians or patient representatives) |
| McClarey, 1999 [ | Not reported | Not reported | • Professional guideline groups • Health care professionals • Patient representatives |
| Oxman, 2006 [ | Not reported | Delphi technique | • Experts • Potential end users • Public • Others |
| Ketola, 2007 [ | Not reported | Not reported | • Specialist society • Board members of guideline developing organization |
| Reveiz, 2010 [ | > 12 | Workshop, consensus meeting | • Experts • External guideline developers • Methodologist • End users |
| Atkins, 2012 [ | Not reported | Not reported | • Clinicians • Professional organizations • Policymakers • Payers (e.g., health plans) • Government bodies • Quality organizations • Patient representatives |
| Schünemann, 2014 [ | Not Reported | Not reported | • Clinicians • Professional societies • Policymakers • Payers • Public |
| Reddy, 2014 [ | Not Reported | Not reported | Not reported |
| Mounesan, 2016 [ | Range (5–15) | Face-to-face meeting | • Experienced family physicians • Management representatives |